



UNIVERSITY OF LEEDS

This is a repository copy of *Identification of natural inhibitor against L1  $\beta$ -lactamase present in Stenotrophomonas maltophilia*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/192539/>

Version: Accepted Version

---

**Article:**

H, SK, Jade, D, Harrison, MA [orcid.org/0000-0002-7826-7472](https://orcid.org/0000-0002-7826-7472) et al. (1 more author) (2022) Identification of natural inhibitor against L1  $\beta$ -lactamase present in *Stenotrophomonas maltophilia*. *Journal of Molecular Modeling*, 28. 342. ISSN 1610-2940

<https://doi.org/10.1007/s00894-022-05336-z>

---

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022. This is an author produced version of an article published in *Journal of Molecular Modeling*. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**Identification of natural inhibitor against L1  $\beta$ -lactamase present in  
*Stenotrophomonas maltophilia*.**

**Sreenithya K H<sup>1</sup>, Dhananjay Jade<sup>2</sup>, Michael A. Harrison<sup>2</sup>, and Shobana Sugumar\*<sup>1</sup>**

<sup>1</sup>*Department of Genetic Engineering, School of Bioengineering, College of Engineering and  
Technology, SRM Institute of Science and Technology, Kattankulathur, India*

<sup>2</sup>*School of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, UK,*

\*Corresponding author, e-mail: shobanas@srmist.edu.in

Received [Dates will be filled in by the Editorial office]

## Abstract

Antibiotic resistance is threatening the medical industry in treating microbial infections. Many organisms are acquiring antibiotic resistance because of the continuous use of the same drug. Gram-negative organisms are developing multi-drug resistance properties (MDR) due to chromosomal level changes that occurred as a part of evolution or some intrinsic factors already present in the organism. *Stenotrophomonas maltophilia* falls under the category of Multidrug-Resistant organism. WHO has also urged to evaluate the scenario and develop new strategies for making this organism susceptible to otherwise resistant antibiotics. Using novel compounds as drugs can ameliorate the issue to some extent. The  $\beta$ -lactamase enzyme in the bacteria is responsible for inhibiting several drugs currently being used for treatment. This enzyme can be targeted to find an inhibitor that can inhibit the enzyme activity and make the organism susceptible to  $\beta$ -lactam antibiotics. Plants produce several secondary metabolites for their survival in adverse environments. Several phytoconstituents have antimicrobial properties and have been used in traditional medicine for a long time. The computational technologies can be exploited to find the best compound from many compounds. Virtual screening, molecular docking, and dynamic simulation methods are followed to get the best inhibitor for L1  $\beta$ -lactamase. IMPPAT database is screened, and the top hit compounds are studied for ADMET properties. Finally, four compounds are selected to set for molecular dynamics simulation. After all the computational calculations, Withanolide R is found to have a better binding and forms a stable complex with the protein. This compound can act as a potent natural inhibitor for L1  $\beta$ -lactamase.

**Keywords:** L1  $\beta$ -lactamase - Virtual screening - Docking - Molecular Dynamics

## Introduction

Antibiotics have played an imperative role in treating microbial infections and achieving amelioration in medicine and surgery [1]. Life expectancy has increased since the discovery and use of antibiotics because they act by altering the course of bacterial diseases [2][3]. However, the overuse of antibiotics aided in developing resistance in some microbes [4]. It was found that there is a link between antibiotic use and the establishment and spread of antibiotic-resistant bacterial strains (The antibiotic alarm 2013). Gene encoding antibiotic resistance can be inherited from relatives or nonrelatives on mobile genetic components like plasmids in bacteria. The HGT (Horizontal Gene Transfer) mechanism can transfer antibiotic resistance between bacteria species. Mutation can also be the reason behind the rise in antibiotic resistance. Antibiotics can phase out drug-sensitive organisms, but the resistant ones that are naturally selected are left behind to multiply. Over prescription of antibiotics is one of the most important reasons behind the emergence of antibiotic resistance. Antibiotic resistance is one of the major problems concerning the health field worldwide. In India, over 56,000 newborns die yearly from sepsis caused by antibiotic-resistant organisms resistant to first-line antibiotics [5]. The antimicrobial resistance property of Gram-negative bacteria (GNB) makes it cumbersome for physicians to treat ICU patients. 45%-70% of ventilator-associated pneumonia cases (VAP)[6] and about 20% - 30% of catheter-related blood-infection cases are caused by GNB. ICU-acquired sepsis-like surgical site infections and UTIs are some common GNB infections among nosocomial patients in hospitals. To overcome the current antibacterial resistance menace, there is an escalated demand to discover novel antibiotics against those neglected targets (Worthington and Melander, 2013). Most antibiotics are attenuated by enzymatic hydrolysis or degradation; in some cases, non-enzymatic mechanisms contribute to antibiotic resistance [7]. Both enzymatic and non-enzymatic mechanisms of resistance can either be intrinsic (effect of some intrinsically present chromosome) or may be acquired over time as a result of mutation[8] [9]. Bacteria utilize mechanisms like efflux pump, reduced outer membrane permeability, drug target modification, and drug inactivation by  $\beta$ -lactamase enzymes to attenuate the drug effects.[10]

$\beta$ -lactamases are a group of enzymes capable of hydrolyzing the amide bond in the  $\beta$ -lactam ring of  $\beta$ -lactam antibiotics such as carbapenems, penicillin, and cephalosporin and monobactam [11]. The two families of  $\beta$ -lactamases include "Metallo- $\beta$ -lactamase" and "Serine- $\beta$ -lactamases"[12]. Serine-based  $\beta$ -lactamases belong to classes A, C, and D. Conversely, Class B enzymes bind one or two metal ions, usually  $Zn^{2+}$ , and play a crucial part in their catalytic activity earning them the name metallo-lactamases (MBL). The effect of metal ion binding to the active site is found to enhance the catalytic significance of the enzyme. In the case of São Paulo metallo- $\beta$ -lactamase-1, the presence

of two zinc ions at the active site provides a closed conformation and enhances the catalytic property. Meanwhile, the presence of one or no zinc gives an open conformation to the active site [13]. Similarly, the double zinc coordination at the active site of New-Delhi Metallo- $\beta$ -lactamase 1 is necessary for binding antibiotics (ampicillin). Also, it restricts the motion in the loop region [14]. Based upon the substrate profile, protein sequence, and slight changes in the active site configuration for two  $Zn^{2+}$  ions, MBL proteins are divided into three subclasses: B1, B2, and B3. MBLs belonging to the B1 and B3 classes can hydrolyze practically every antibiotic with  $\beta$ -lactam rings, including the most recently produced carbapenems. Class B2 enzymes, on the other hand, have a narrow carbapenem substrate profile and weak action against penicillin and cephalosporins [15]. L1- $\beta$ -lactamases belong to the MBL family, while L2- $\beta$ -lactamase belongs to the Serine  $\beta$ -lactamase family [16]. Multiple biochemical studies support several crystal structures of L1 and other B3 MBLs complexed with antibiotics [17][18]. Even though the B3 MBLs are structurally well-conserved, especially at the active site flanked with two zinc ions, the sequence identity is 23–35% [17][19]. Inhibitors for  $\beta$ -lactamase are prioritized to aggrandize treatment potency with  $\beta$ -lactam antimicrobials and avoid antimicrobial resistance.  $\beta$ -lactamase inhibitors may act as "competitive inhibitors" or "suicide inhibitors" that can permanently render the enzyme inoperable utilizing secondary chemical reactions in the active site. Clavulanic acid, a natural product discovered in 1976 and used with ticarcillin and amoxicillin, is the first clinically successful  $\beta$ -lactamase inhibitor. It was quickly followed by introducing sulbactam and tazobactam, synthetic penicillin-based sulfone-lactamase inhibitors combined with ampicillin and piperacillin. The  $\beta$ -lactamase inhibitors that are clinically used for treatment like clavulanic acid have now become ineffective [20].

Pathogens encompassing  $\beta$ -lactamase enzymes have sprung up in clinical fields and the environment. *Stenotrophomonas maltophilia* is an emerging prokaryotic, gram-negative, nosocomial, multi-drug resistant non-fermentative bacteria. The organism has emerged as an important hospital-acquired pathogen over the past decade. Treatment of infections due to this bacterium is challenging due to its multi-drug resistance (MDR). MDR is the property or ability of an organism to resist the effect of at least three antibiotics. The MDR in *S.maltophilia* is due to the intrinsic multidrug resistance phenotype, which involves the impact of several chromosomal determinants. *S.maltophilia* expresses specialized efflux pumps that can pump out a broad spectrum of drugs, especially  $\beta$ -lactams. One among them, SmeDEF, is the most effective one and is efficient in the expulsion of quinolones and aminoglycosides [21]. The L1  $\beta$ -lactamases or Zn  $\beta$ -lactamases and L2  $\beta$ -lactamases with serine in the active site are the two chromosomal  $\beta$ -lactamases produced by *S.maltophilia* [22]. The L1 in *S.maltophilia* belongs to the B3 subclass of MBL [23]. The protein is a tetramer with  $\alpha\beta/\beta\alpha$  folds. The active site is found between the two  $\beta$  sheets containing two zinc

atoms, and the side chains that coordinate the metal ions are at the bottom of the active site. The amino acids bound to Zn1 are His196, His118, and His116 in 2.1-2.2 Å distance range. Asp120, His263, and His121, are bound to Zn2 with distances of 3.0, 2.5, and 2.1 Å, respectively [24]. An increase in the inhibitory capacity of L1  $\beta$ -lactamase can be attributed to the two zinc ions present at the active site of the enzyme. Zinc plays a catalytic role in the enzyme. It stabilizes the tetrahedral transition state, protonates the nitrogen atom in the  $\beta$ -lactam ring, and causes a nucleophilic attack on the hydroxide group in the carbonyl carbon, thereby forming a tetrahedral intermediate [25][26]. The ligands mainly bind to the metal ion. The binding pocket of the protein provides a broader region for many  $\beta$ -lactam antibiotics to bind [24]. It has thus become an increasing concern to find inhibitors against  $\beta$ -lactamases that can render the enzyme ineffective and make the organism more susceptible to antibiotics.

Plants provide a vast range of medications used to treat several ailments. Many laboratories continue to screen medicinal plants for new antimicrobial medication candidates that can slow pathogen development or kill without causing toxicity to the host [27][28]. Plant-based antimicrobials hold significant therapeutic potential, making them a massive untapped supply of pharmaceuticals. They are found to help treat infectious disorders by avoiding most of the adverse side effects that are usually common when synthetic antibiotics are used for treatment. Plant-derived antimicrobials are biodegradable and are relatively safer drugs. Even though many antibiotics are available, the search for plant-based compounds to combat fungal and bacterial infections will continue[29].

In the current study, we screened the phytochemicals from IMPPAT database [30] to find an inhibitor against L1  $\beta$ -lactamase of *Stenotrophomonas maltophilia*. After molecular docking, the compounds having good binding energy were selected for ADME and PAINS-remove studies (toxicity analysis). The compounds that passed the toxicity studies were set to Molecular Dynamic (MD) simulation to test the stability of the complex. Thus, the results will give a novel inhibitor identified for L1  $\beta$ -lactamase of *S.maltophilia*.

## **Materials and methods**

### **Virtual screening**

### **Protein structure preparation**

The X-ray crystallography structure of Metallo  $\beta$ -lactamase L1 from *Stenotrophomonas maltophilia* with hydrolyzed imipenem complex structure (PDB id: 6UAF [24]) was downloaded from the Protein data bank (RCSB-PDB) [25][31] and utilized for ensuing studies (**Figure 1**). This protein structure resolution is 1.90 Å. The sequence length of Metallo-  $\beta$ -lactamase L1 is 293, and the downloaded crystal protein structure has 266 amino acids (residue number 23 to 289) with two Zn ions. However, missing residues present at the N-terminal and C-terminal were unresolved and these unsolved residues are not affecting the binding interaction as they are away from the active site. The protein structure was prepared by adding hydrogen and subjected to energy minimization through UCSF-Chimera software. For refining the structure and minimizing the energy of the selected protein, UCSF-Chimera software was employed.

### **Ligand library preparation**

The ligand library for virtual screening of suitable inhibitor molecules against L1  $\beta$ -lactamase was downloaded from the IMPPAT database[32]. The three-dimensional structures of the phytochemicals were downloaded in PDB format and then converted to PDBQT using OpenBabel and maintained in a folder. The phytochemicals for which there was no availability of 3D structure were excluded from the study. A total of 7937 compounds were collected from the IMPPAT database.

### **Molecular Docking**

Molecular docking techniques are of great importance in the discovery of novel drugs. The methodology involves the prediction of the pose, virtual screening, and estimation of binding affinity of the ligands to the protein. The structure-based screening was performed using AutoDock Vina[33]. The protein in PDB format was converted to PDBQT format using OpenBabel software[34]. Kollman charges method was utilized to add polar hydrogen and charges. The grid point in XYZ, 46Å×62Å×82Å (x, y, and z), and the grid box center 20.245×24.393×0.68, with 0.375Å spacing, were assigned to the protein. This information was saved in the conf.txt file. The grid map was calculated using Autogrid4. The remaining docking computation parameters were maintained unchanged. The target protein, the ligands, conf.txt, and script files were maintained in the same directory to perform docking. After docking, every ligand produced two output files, log.txt and out.pdbqt. A total of 10 conformations were taken into consideration for every ligand. The log.txt file contained the docking score of all the ten conformations. pdbqt had the structural information of the complex. A python script (<https://vina.scripps.edu/manual/>) was run to obtain the compounds with a high dock score (minimum binding energy). The interaction between protein-

ligand complexes was calculated using PLIP [35]. A standard  $\beta$ -lactam drug, imipenem, was docked with the protein as a control.

### **ADME AND PAINS analysis**

After molecular docking we performed ADME (Absorption, Distribution, Metabolism, Elimination) and PAINS-remover calculation to verify the pharmacokinetic ability of the selected compounds obtained after screening based on molecular docking. Lipinski's rule, Ghose filter, Verber's rule, Muegge's rule, Egan rule, water solubility, lipophilicity, hepatotoxicity, etc, are some of the main drug-likeness rules. Along with ADME calculation we performed the PAINS (pan-assay interference compounds) calculation. Through this calculation we removed the compounds that may give false-positive compounds results when predicting binding sites. Compounds with ADME and PAINS alerts must be eliminated from the study. For calculation of ADME, we use the Swiss-ADME and for calculation of PAINS we used PAINS-remover web online tools.

### **Molecular Dynamics (MD) Simulation**

For performing MD, GROMACS (Version-4.6.5) software was used. GROMACS 53a6 force field was selected for generating the protein topology file. The binding orientation of the selected hit compounds were obtained from the docking site and the ligand topology was created using the PRODRUG online tool. For solvation, the complex was placed in a triclinic box and solvated with spc216 (simple point charge) water. Na<sup>+</sup> or Cl<sup>-</sup> ions were then added to the system for neutralization. The overall system (ions, water and protein-ligand complex), was relaxed by running energy minimization with the steepest descent. PME algorithms were used for estimating electrostatic interaction. For this study, we set the pme\_order to 4, fourier spacing to 0.16, and scale at 310 K. Next, the entire system was specified for thermal equilibration (NVT step) for 1 ns using Modified Berendsen Thermostat (V-rev100ns for selected virtual hit compounds). NPT was performed at 300 K using V-rescale, the pressure coupling (P-coupling), and temperature coupling (T-coupling). 100 ns MD simulation was performed without position restraints. The output was saved every 2 ps. At every 10 ps, the velocities and coordinates, nstvout and nstxout, respectively, were also held. We set the 1.0 nm cut-offs for coulombic (rcoulomb) and Van der Waals force (rvdw). PME (Particle Mesh Ewald) and PBC (Periodic Boundary Conditions) were used in 100 ns MD simulation to calculate the long-range electrostatic interactions. MD simulation results were analyzed by plotting the graph of RMSD (Root Mean Square Deviation), RMSF (Root Mean Square Fluctuation), and Rg (Radius of gyration). They were calculated using g\_rms, g\_rmsf, and g\_gyrate.



Along with this we checked the changes in the secondary structure of protein using the do\_dssp program.

### **Binding Free Energy Calculation using MM-PBSA**

Once we finish the 100 ns Simulation, we use the stable region to calculate the binding free energy (BFE). Binding free energy calculation is a critical approach to study the reciprocal recognition and binding of protein and their ligands. The negative and positive values of free energy show the possibility of a reaction, and the importance of binding free energy is an accurate standard for evaluating the bending degree of protein receptors to ligands[36]. The binding free energy for selected hit compounds and the energy change under vacuum were calculated using Molecular Mechanics energies combined with Poisson-Boltzmann (MM-PBSA) method by g\_mmpbsa Tool [37]. PB shows the polar part of solvent-free energy of systems calculated by the Poisson-Boltzmann (PB) equation. The non-polar part of solvent-free energy systems is fitted by the solvent-accessible surface area (SASA). The MMMPBSA calculation is as follows;  $\Delta G_{bind} = \Delta E_{vdw} + \Delta E_{ele} + \Delta G_{pol} + \Delta G_{nonpol} - T\Delta S$

The  $\Delta E_{vdW}$  and  $\Delta E_{ele}$  are van der Waals and electrostatic components, respectively, and the polar and nonpolar components are indicated as  $\Delta G_{pol}$  and  $\Delta G_{nonpol}$ , respectively.  $T\Delta S$  is the temperature and entropic contribution towards BFE. BFE plays a significant role in drug discovery, giving a quantitative estimation of the ligand binding to the protein. The q\_mmpbsa tool calculated MM-PBSA after extracting the stable segment in the trajectory file.

## **Results and Discussion**

### **Virtual screening**

Structure-based virtual screening was used to screen down the compounds downloaded from IMPPAT (Indian Medicinal Plants, Phytochemistry and Therapeutics) database using molecular docking techniques. Molecular docking was performed using standard default parameter to calculate the binding energy. 7937 IMPPAT phytochemical compounds were docked with the target protein (6uaf) and the compounds with best dock score (more negative value) was considered to be the best bonding. Out of 7937 phytochemical, we selected top eight compounds

based on their minimum binding energy from 10 conformation generated by all the compounds. The selected eight compounds are Withanolide R (-10.26 kcal/mol), Withanolide A (-9.59 kcal/mol), 27-Deoxywithaferin (-9.98 kcal/mol), Demissidine (-9.3 kcal/mol), Pibenzimol (-9.3 kcal/mol), Crinasiatine (-9.2 kcal/mol), 3-Methylcholanthrene (-8.7 kcal/mol) and Withanolide Q (-6.14 kcal/mol). These selected eight compounds were further screened down by applying the ADME and PAINS parameter to get the good drug compound.

#### **ADME and PAINS analysis:**

All the top eight compounds, after docking, were studied for ADMET and PAINS properties. All the compounds had a molecular weight of less than 500 Daltons and logP <5. One violation of the Ghose rule occurs for all the compounds except for 3-Methylcholanthrene (-8.7). One of the selected compounds, Demissidine, with a dock score of -9.3, violated one Lipinski's rule and one Muegge's rule. 3-Methylcholanthrene violated one Lipinski's rule and two Muegge's rules. All the compounds were AMES non-toxic. The ADME study results are given in **Table 3**. After ADME calculation, we run the PAINS-remover to check if the compounds represent poor choices for drug development. None of the compounds showed PAINS alert. After the ADME and PAINS analysis, we selected four compounds which showed no PAINS alert, satisfied most of the drug-likeness parameters, are AMES non-toxic and have very low CYP p450 inhibition. The selected compounds are Withanolide Q, Withanolide A, Withanolide R, and 27-Deoxywithaferin. These compounds are present in, and can be extracted from, the roots of *Withania somnifera* (ashwagandha). These selected four compounds were finalized to proceed for the MD simulation.

#### **Molecular Docking Analysis:**

Based on binding energy, ADME and PAINS analysis we select the four compounds. 25-Deoxywithaferin, Withanolide A, Withanolide Q, and Withanolide R compounds interaction were calculated using the PLIP online tool. It shows the hydrogen bond and hydrophobic bond formed with protein and ligand, as well as it shows the interaction between protein-ligand complex with two zinc atoms present in the binding pocket. Further, we included Imipenem, the known standard reference compound (control) for comparison. It is an intravenous  $\beta$ -lactam antibiotic used for the treatment of infections. All these chosen compounds bind in the same declaration region near Zn ions, as shown in **Figure 2**. These four compounds and the control binding energies are shown in **Table 1**. When compared to other selected hit compounds, Withanolide R shows the most potent binding energy which is -10.26 Kcal/mo. There are two Zn ions present in L1  $\beta$ -lactamase that interact with protein as well as the ligand. Compound Withanolide A and Withanolide R take part

in interaction with Zn (**Figure 4** and **Figure 6**) and other two compounds Withanolide Q and 27-Deoxywithaferin do not interact with Zn ions (**Figure 3** and **Figure 5**). The amino acids involved in formation of hydrogen bonds, hydrophobic interaction, salt bridge formation as well as interactions with Zn ions are mentioned in **Table 2**. For protein and 27-Deoxywithaferin complex, 302 Zn ion interactions are established with Asp109 (2.8 Å) and His110 (2.0 Å) and 303 Zn ion interact with His105 and His181 at 2.0 Å (**Figure 3.A** and **Figure 3.B**) (**Table 2**). Compound 27-Deoxywithaferin shows the hydrophobic interaction with Leu59, Phe145, Ile149, His246, and Lys277 (**Figure 3.C**). In the case of Withanolide A-protein complex, Zn ion shows the interaction with amino acids and ligand shown in **Figure 4.A** and **Figure 4.B** (**Table 2**). This complex shows the hydrogen and hydrophobic interaction with Leu207, Ser208, Lys277 and Tyr32, and hydrophobic interaction with Trp38, Phe145, His246, Ala249, Tyr270, Ala274 (**Figure 4.C**). Along with these interactions we observe the salt bridge formation at His105, His107, His110, His181 and His246 (**Table 2** and **Figure 4.C**). From the selected compounds, Withanolide Q-protein complex, Zn ions do not show any interactions with the ligand, but form bonds with amino acids in the vicinity. The Zn302 interacts with His109, His110, and His246 at distance 2.1 Å, 2.2 Å and 2.1 Å respectively and Zn303 interact with His105 (2.0 Å), His107 (2.2 Å) and His181 (2.2 Å) as shown in **Figure 5.A**, **Figure 5.B** and **Table 2**. This compound take part in hydrogen and hydrophobic interaction with protein as shown in **Table 2** and **Figure 5.C**. Withanolide R shows the interaction with Zn ions. Both Zn ions forms interaction with the compound as well as with amino acids as shown in **Figure 6.A**, **Figure 6.B** and **Table 2**. Hydrogen bonds interaction were formed with Leu207, Ser208, His246, and Lys277 and hydrophobic interaction were established with His107, Phe145, Ile149, His246, Ala249, Tyr270, Ala274, and Lys277 residues (**Figure 6.C** and **Table 2**). Salt bridge interaction with His105, His107, His110, His181, and His246 is also established (**Figure 6.C** and **Table 2**). Among all four compounds, 27-Deoxywithaferin is not involved in forming hydrogen bonds with the protein, or any kind of bond is formed with Zn ions. The control (Imipenem) formed hydrogen bonds with amino acids Tyr32, Ser206, Lue207 and Ser208. Hydrophobic bond is formed with Ala249. It takes part in interaction with both Zn ions. This comparison analysis shows that the known  $\beta$  lactam drug (imipenem) and hit compound have the same pattern of interaction as well as hit compounds binds in the same region where the  $\beta$  lactam drug binds.

#### **Molecular Dynamics (MD) Simulation analysis:**

Selected hit compounds were further subjected to 100 ns MD simulation to analyze the stability of the protein-ligand complex. Through this we investigated the binding mechanism and dynamic

behavior of the complexes. The receptor-ligand conformational stability was studied through RMSD, RMSF, and Radius of gyration. We calculated the hydrogen bond between protein-ligand and protein solvent throughout the 100 ns MD simulation. We checked the changes in the secondary structure when selected compounds were bound to the protein. After that, MMPBSA was computed to calculate binding free energy.

We calculated the RMSD value to check the change in the  $\alpha$  carbon of the ligand-receptor complex. An elevation of RMSD value at the starting stage of MD simulation up to 0.35nm was observed for 27-Deoxywithaferin and Withanolide R. Withanolide A and Withanolide Q showed the most RMSD value (0.45 nm), and it gradually increased up to 15 ns simulation. 27-Deoxywithaferin showed slight increase in the RMSD value at initial stage upto 1 ns and then there was a sudden decrease in it. After that the RMSD value slowly increased upto 10 ns. Then the RMSD became constant with slight fluctuation throughout the 100 ns simulation between 0.4-0.5 nm (**Figure 7**). In the case of Withanolide R, there was more oscillation in value up to 5 ns, after that it showed an increase in the RMSD value (0.55 nm) up to 15 ns. Up to 43 ns, the RMSD remained almost constant. There was a sudden decrease in RMSD between 0.40-0.55 nm up to 57 ns and then it gradually increased up to 100 ns MD simulation. In the case of Withanolide A and Withanolide Q, the same pattern of fluctuation was observed up to 35 ns simulation. After that Withanolide A showed a decreased RMSD value between 0.45-0.55 nm and Withanolide-Q showed a slight increase between 0.55-0.60 nm throughout the 100 ns simulation (**Figure 7**).

Further we checked the momentum of each residue throughout the simulation when the ligand binds to the protein in the presence of Zn ions. For that, the RMSF was plotted against residues (**Figure 8**). The plot shows that all compounds show the same protein fluctuation pattern. However, when Withanolide R binds to protein, the initial amino acid shows a more RMSF value, and other amino acids indicate the same fluctuation pattern. Residues between 210-230 showed a slight difference in RMSF value. In the case of Withanolide Q, the binding to protein shows the same pattern of fluctuation by all amino acids, but residues between 87-100 show a more RMSF value when compared with others. When Withanolide A binds to the protein, all amino acids show a smaller RMSF value than others. 27-Deoxywithaferin complexed with the protein shows the same fluctuation pattern throughout the simulation, but some amino acids show a lower RMSF value (140-150 residues and 210-223 residues). RMSF is more at residues from 245 to 260 (**Figure 8**). This increase and decrease in the fluctuation are possibly due to interaction between the hit compound and the protein helix, small  $\beta$ -sheets, and the loop region of the protein. The RMSF plots backbone shows more fluctuation in the loop and helix regions.

The compactness level of the protein-ligand complex in the presence of Zn ions was checked by calculating the radius of the gyration (Rg) plot (**Figure 9**). We used the 100 ns MD simulation trajectory file for this calculation and plotted the gyration plot using Rg vs. time shown in **Figure 9**. All selected hit compounds initially showed the Rg value between 1.82-1.85 nm. Then it decreased till 5 ns. Withanolide Q and Withanolide R showed a slight increase in the Rg value up to 6 ns, and after that, the same pattern of fluctuation till 25 ns was observed. In the case of 27-Deoxywithaferin, the Rg value had a steady fluctuation. For Withanolide A, the Rg value increased to 7 ns and then decreased to 20 ns. After some time, there was a sudden increase in Rg value (1.9 nm Rg). After this, the Rg decreased till 50 ns and then there was a steady increase and decrease till the end of 100 ns simulation. At 45 ns, compounds 27-Deoxywithaferin and Withanolide A showed the same pattern of Rg, which was between 1.78-1.83 nm. At the same point (45 ns), Withanolide Q and Withanolide R showed a slow increase in Rg value, and both compounds showed the same pattern of fluctuation up to 100 ns simulation.

The H-bond interaction between protein-ligand and protein-solvent was also calculated (**Figures 10 and 11**). Withanolide R showed a better hydrogen bond interaction than the other compounds. This compound formed 0-6 hydrogen bonds in 100 ns MD simulation. At initial simulation time up to 45 ns, 0-2 hydrogen bonds were established in the protein-ligand complex. At 73-92 ns, the number of hydrogen bonds increased to 2. 27-Deoxywithaferin (Magenta color), Withanolide A (Purple color), and Withanolide Q (Green color) showed the same pattern of hydrogen bond formation **Figure 10**. The H-bond interactions formed between the protein and the solvent were also calculated. 420-540 H-bonds were established between the protein and solvent (**Figure 11**). Withanolide R had the highest number of hydrogen bond interactions among all the other compounds, and Withanolide Q had the least. In the case of 27-Deoxywithaferin and Withanolide A, the same pattern of hydrogen bond interactions between protein-solvent was observed.

Throughout the simulation, secondary structure changes were analyzed using the do\_dssp program (**Figure 12**). For this program, the trajectory file for 100ns was used to compute the secondary structure for every frame. When the complexes are formed with the protein by selected hit compounds, some changes in the conformational behavior and degree of protein folding were observed. This depended on its secondary structure. When we compared selected hit compounds bound to the protein, no more secondary structural changes were observed. We observed some minor changes in the secondary structure, which is observed in  $\beta$ -sheets (Red color) to turn (Yellow color), coil (White color) to turn (Yellow color), and turn (Yellow color) to bend (Green color).

Further, we calculated the binding free energy for the selected hit compounds (**Table 4**). Among the selected hit compounds, Withanolide R showed the most binding free energy, -80.003 kJ/mol, and

compound 27-Deoxywithaferin showed the least binding free energy, -28.096 kJ/mol. The other two compounds binding energy are shown in **Table 4**. The MMPBSA energy is known as approximate free energies of binding. Stronger critical interaction gives more negative values.

### **Discussion:**

*Stenotrophomonas maltophilia*, a multidrug-resistant organism, makes treating the infections caused by the bacteria very difficult. This organism can resist several antibiotics that are currently prescribed for microbial infections. Some antibiotics like fluoroquinolones (FQs), trimethoprim-sulfamethoxazole (SXT), ticarcillin clavulanate, tetracyclines, and ceftazidime are found to have *in vitro* activity against this bacteria; however, the clinical evidence for their use is limited [38][39] WHO has also urged on to come up with novel strategies to make the organism vulnerable to the antibiotics available. The presence of  $\beta$ -lactamase enzymes in the extracellular space makes the organism resistant to a broad spectrum of  $\beta$ -lactam antibiotics. There are no specific inhibitors discovered that inhibit the L1  $\beta$ -lactamase. The active site of this enzyme contains two zinc ions at 302 (Zn1) and 303 (Zn2). Targeting the active site zinc ions will help inhibit the catalytic property of the protein and thus can lead to the discovery of a novel inhibitor specifically for L1  $\beta$ -lactamase that can compete with  $\beta$ -lactam antibiotics to bind at the active site.

An *in-silico* approach toward discovering novel inhibitor compounds is less expensive and recommendable in today's scenario. Many research data suggest that molecular docking and dynamics approaches in studying protein-ligand stability are effective [40][41]. With the development of molecular dynamics simulation techniques in the 1970s, the usage of the computational approach got elevated in drug discovery [42][43][44]. In the present study, a virtual screening, molecular docking, and MD simulation approach is carried out on plant-based compounds to screen the inhibitor for L1  $\beta$ -lactamase from the 7937 phytochemicals from the IMPPAT database. The docking results were compared with that of the reference compound (imipenem). It is a standard  $\beta$ -lactam antibiotic compound discovered by merck scientist Burton Christensen, William Leanza and Kenneth Wildonger in the mid-1970. L1  $\beta$ -lactamase mainly inhibits imipenem. The selected hit metabolites had better dock score and binding interactions than imipenem, suggesting that they can compete with the  $\beta$ -lactam antibiotics (substrates for  $\beta$ -lactamase) and bind to the active site and block it, thereby reducing the ability of the enzyme in hydrolysis of the antibiotics. Withanolide A, Withanolide Q, Withanolide R, and 27-Deoxywithaferin were selected by Molecular docking, ADME and PAINS-remover studies. All the four compounds are derivatives of Withanolides in *Withania somnifera* (ashwagandha). Most of the pharmacological properties of *W.somnifera* are rendered by Withanolides. They have many

biological activities, including immunoregulatory, anticancer, antimicrobial, anti-inflammatory, leishmanicidal, and trypanocidal [45]. Withanolide A has suitable neuropharmacological activities that aid in the outgrowth of the neurite. Thus it can reverse neuritic atrophy and help to reconstruct the synapse [46]. Withanolide Q is reported to have a modulating effect on several SARS-CoV-2 proteins [47]. 27-Deoxywithaferin is found to have antibacterial properties [48] and has the potential to inhibit spike protein of SARS-CoV-2, while Withanolide R can inhibit the main protease of SARS-CoV-2 [49]. These data suggest the strong antimicrobial property of these phytochemicals. 27-Deoxywithaferin (BE -9.98 kcal/mol) showed a stable and lower RMSD value than all the other compounds, and thereby it is understood that this complex shows a minimal deviation in the path from the actual when compared to other complexes. On the other hand, RMSF result also shows the same pattern of fluctuation throughout the simulation. Comparison of the RMSF of the hit compounds suggest that all these compounds binding to the zinc containing L1  $\beta$ -lactamase does not show much difference and even the amino acids present in the active site does not show much fluctuation. There were fluctuations at some residues, but none of these residues are present in the loop region, and hence it did not affect the stability of the complexes during the 100 ns simulation. Even though 27-Deoxywithaferin had a good RMSD and RMSF, the compound did not form any hydrogen bonds with the protein, which resulted in the least binding energy, and it did not interact with zinc atoms at the active site. To study the compactness of the complex formed between protein and selected hit compounds in the presence of Zn ions, the Rg plot was analyzed. From the Rg plot, it can be elucidated that the compactness level of the 27-Deoxywithaferin protein complex was stable and constant throughout the simulation, but at initial time period it showed a decrease in the compactness up to 5 ns but after 5 ns it shows the steady and stable compactness compared to the other three complexes. Withanolide A showed the least compactness. Withanolide Q and R showed the same pattern of compactness as their Rg was stable throughout the 100 ns simulation. We can get an idea about the binding strength by analyzing the number of H-bonds established between the compounds, and the number of hydrogen bonds based between the compounds gives an idea about the strength of binding.

Withanolide R established the most significant number of hydrogen bonds (between 0 to 6) with the residues at the active site of the target protein. This compound also had a better hydrogen bond interaction with the solvent molecules. Among the four compounds, Withanolide R showed the slightest fluctuation which signifies the stability of the complex, and the MMPBSA score was maximum (-80.003). This can be because of its strong binding to the residues and zinc ions at the active site. All the data thus obtained based on computational calculations can give ideas for designing a potent drug that can specifically target the L1  $\beta$ -lactamase and inhibit its action.

## Conclusion

We successfully screened the phytochemicals from the IMPPAT database using Molecular docking , ADME and PAINS remover techniques. Good dock scores were obtained for ligands interacting with the amino acid residues and zinc ions at the active site. The ADME and PAINS-remove study on the top hit compounds resulted in four phytochemicals that satisfied the drug-likeness and lead likeness properties. We also carried out an MD simulation to find the most stable complex. From the entire study, the compound Withanolide R present in *Withania somnifera* (ashwagandha) formed a stable binding conformation at the active site. It had the best dock score, binding energy, and the highest number of interactions with the active site residues. The conformational fluctuations were also less. The highest number of interactions at the active site and stability in binding can make the compound a potent inhibitor of the enzyme. However, in vitro studies have to be conducted to thoroughly understand and thereby confirm the inhibitory property of Withanolide R on L1  $\beta$ -lactamase of *S. maltophilia*.

## Declaration

**Funding:** This work did not receive any specific grant from funding agencies in the public, commercial or non-profit sector

**Conflict of interest:** The authors declare that they have no conflict of interest toward any individual or organization.

**Data availability:** Not applicable

### Authors' contribution:

Shobana Sugumar: Research idea, Manuscript

Sreenithya K H: Experimental works, Result Interpretation, Manuscript

Dhananjay Jade: Result Interpretation

Michael A. Harrison: Result Interpretation, Manuscript

## Reference

1. Gould IM, Bal AM (2013) New antibiotic agents in the pipeline and how they can help overcome microbial resistance. *Virulence* 4:185–191. <https://doi.org/10.4161/viru.22507>
2. Rossolini GM, Arena F, Pecile P, Pollini S (2014) Update on the antibiotic resistance crisis. *Curr. Opin. Pharmacol.* 18:56–60
3. Piddock LJV (2012) The crisis of no new antibiotics-what is the way forward? *Lancet Infect. Dis.* 12:249–253
4. Read AF, Woods RJ (2014) Antibiotic resistance management. *Evol Med Public Heal*



2014:147. <https://doi.org/10.1093/emph/eou024>

5. Wattal C, Kler N, Oberoi JK, et al (2020) Neonatal Sepsis: Mortality and Morbidity in Neonatal Sepsis due to Multidrug-Resistant (MDR) Organisms: Part 1. *Indian J. Pediatr.* 87:117–121
6. Barbier F, Andremont A, Wolff M, Bouadma L (2013) Hospital-acquired pneumonia and ventilator-associated pneumonia: Recent advances in epidemiology and management. *Curr. Opin. Pulm. Med.* 19:216–228
7. Alekshun MN, Levy SB (2007) Molecular Mechanisms of Antibacterial Multidrug Resistance. *Cell* 128:1037–1050
8. Luyt CE, Bréchet N, Trouillet JL, Chastre J (2014) Antibiotic stewardship in the intensive care unit. *Crit Care* 18:. <https://doi.org/10.1186/s13054-014-0480-6>
9. Bassetti M, De Waele JJ, Eggimann P, et al (2015) Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. *Intensive Care Med.* 41:776–795
10. Kapoor G, Saigal S, Elongavan A (2017) Action and resistance mechanisms of antibiotics: A guide for clinicians. *J. Anaesthesiol. Clin. Pharmacol.* 33:300–305
11. Hamed RB, Gomez-Castellanos JR, Henry L, et al (2013) The enzymes of  $\beta$ -lactam biosynthesis. *Nat. Prod. Rep.* 30:21–107
12. Rahman M, Khan MKA (2020) In silico based unraveling of New Delhi metallo- $\beta$ -lactamase (NDM-1) inhibitors from natural compounds: a molecular docking and molecular dynamics simulation study. *J Biomol Struct Dyn* 38:2093–2103. <https://doi.org/10.1080/07391102.2019.1627248>
13. Chen J, Wang J, Pang L, et al (2021) Deciphering molecular mechanism behind conformational change of the São Paulo metallo- $\beta$ -lactamase 1 by using enhanced sampling. *J Biomol Struct Dyn* 39:140–151. <https://doi.org/10.1080/07391102.2019.1707121>
14. Chen J, Wang J, Physics WZ-PCC, 2017 undefined Zinc ion-induced conformational changes in new Delphi metallo- $\beta$ -lactamase 1 probed by molecular dynamics simulations and umbrella sampling. [pubs.rsc.org](https://pubs.rsc.org)
15. Palzkill T (2013) Metallo- $\beta$ -lactamase structure and function. *Ann N Y Acad Sci* 1277:91–104. <https://doi.org/10.1111/j.1749-6632.2012.06796.x>
16. Tooke CL, Hinchliffe P, Lang PA, et al (2019) Molecular basis of class A  $\beta$ -lactamase inhibition by relebactam. *Antimicrob Agents Chemother* 63:. <https://doi.org/10.1128/AAC.00564-19>
17. Nauton L, Kahn R, Garau G, et al (2008) Structural Insights into the Design of Inhibitors for the L1 Metallo- $\beta$ -lactamase from *Stenotrophomonas maltophilia*. *J Mol Biol* 375:257–269.

<https://doi.org/10.1016/j.jmb.2007.10.036>






18. Crisp J, Connors R, Garrity JD, et al (2007) Structural basis for the role of Asp-120 in metallo- $\beta$ -lactamases. *Biochemistry* 46:10664–10674. <https://doi.org/10.1021/bi700707u>
19. Wachino JI, Yamaguchi Y, Mori S, et al (2013) Structural insights into the subclass B3 metallo- $\beta$ -lactamase SMB-1 and the mode of inhibition by the common metallo- $\beta$ -lactamase inhibitor mercaptoacetate. *Antimicrob Agents Chemother* 57:101–109. <https://doi.org/10.1128/AAC.01264-12>
20. Chatwin CL, Hamrick JC, Trout REL, et al (2021) Microbiological characterization of VNRX-5236, a broad-spectrum  $\beta$ -lactamase inhibitor for rescue of the orally bioavailable cephalosporin ceftibuten as a carbapenem-sparing agent against strains of enterobacterales expressing extended-spectrum  $\beta$ -lactamases and serine carbapenemases. *Antimicrob Agents Chemother* 65:. [https://doi.org/10.1128/AAC.00552-21/SUPPL\\_FILE/AAC00552-21\\_SUPP\\_1\\_SEQ1.PDF](https://doi.org/10.1128/AAC.00552-21/SUPPL_FILE/AAC00552-21_SUPP_1_SEQ1.PDF)
21. Brooke JS (2012) *Stenotrophomonas maltophilia*: An emerging global opportunistic pathogen. *Clin. Microbiol. Rev.* 25:2–41
22. Looney WJ, Narita M, Mühlemann K (2009) *Stenotrophomonas maltophilia*: an emerging opportunist human pathogen. *Lancet Infect. Dis.* 9:312–323
23. Juan C, Torrens G, González-Nicolau M, Oliver A (2017) Diversity and regulation of intrinsic  $\beta$ -lactamases from non-fermenting and other Gram-negative opportunistic pathogens. *FEMS Microbiol. Rev.* 41:781–815
24. Kim Y, Maltseva N, Wilamowski M, et al (2020) Structural and biochemical analysis of the metallo- $\beta$ -lactamase L1 from emerging pathogen *Stenotrophomonas maltophilia* revealed the subtle but distinct di-metal scaffold for catalytic activity. *Protein Sci* 29:723–743. <https://doi.org/10.1002/PRO.3804>
25. Park H, Brothers EN, Merz KM (2005) Hybrid QM/MM and DFT investigations of the catalytic mechanism and inhibition of the dinuclear zinc metallo- $\beta$ -lactamase CcrA from *Bacteroides fragilis*. *J Am Chem Soc* 127:4232–4241. <https://doi.org/10.1021/ja042607b>
26. Crowder MW, Spencer J, Vila AJ (2006) Metallo- $\beta$ -lactamases: Novel weaponry for antibiotic resistance in bacteria. *Acc Chem Res* 39:721–728. <https://doi.org/10.1021/ar0400241>
27. Farnsworth, Olayiwola Akerele NR, Bingel AS, Soejarto DD, Zhengang & (1985) Medicinal plants in therapy\*
28. Fransworth N (1988) Screening plants for new medicines. In: *Biodiversity*. pp 83–97
29. Sandhya B, Thomas S, Isabel W, Shenbagarathai R (2006) Ethnomedical plants used by the

- Valaiyan community of Piranmalai Hills (reserved forest), Tamilnadu, India - A pilot study. *African J Tradit Complement Altern Med* 3:101–114. <https://doi.org/10.4314/ajtcam.v3i1.31145>
30. Mohanraj K, Karthikeyan BS, Vivek-Ananth RP, et al (2018) IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry and Therapeutics. *Sci Rep* 8:. <https://doi.org/10.1038/s41598-018-22631-z>
  31. Berman HM, Battistuz T, Bhat TN, et al (2002) The protein data bank. *Acta Crystallogr Sect D Biol Crystallogr* 58:899–907. <https://doi.org/10.1107/S0907444902003451>
  32. Mohanraj K, Karthikeyan BS, Vivek-Ananth RP, et al (2018) IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry and Therapeutics. *Sci Rep* 8:4329. <https://doi.org/10.1038/s41598-018-22631-z>
  33. Trott O, Olson AJ (2009) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem NA-NA*. <https://doi.org/10.1002/JCC.21334>
  34. O’Boyle NM, Banck M, James CA, et al (2011) Open Babel: An Open chemical toolbox. *J Cheminform* 3:. <https://doi.org/10.1186/1758-2946-3-33>
  35. Adasme MF, Linnemann KL, Bolz SN, et al (2021) PLIP 2021: Expanding the scope of the protein-ligand interaction profiler to DNA and RNA. *Nucleic Acids Res* 49:W530–W534. <https://doi.org/10.1093/nar/gkab294>
  36. Jespers W, Åqvist J, Gutiérrez-de-Terán H (2021) Free Energy Calculations for Protein–Ligand Binding Prediction. *Methods Mol Biol* 2266:203–226. [https://doi.org/10.1007/978-1-0716-1209-5\\_12](https://doi.org/10.1007/978-1-0716-1209-5_12)
  37. Homeyer N, informatics HG-M, 2012 undefined (2012) Free energy calculations by the molecular mechanics Poisson– Boltzmann surface area method. *Wiley Online Libr* 31:114–122. <https://doi.org/10.1002/minf.201100135>
  38. Samonis G, Karageorgopoulos DE, Maraki S, et al (2012) *Stenotrophomonas maltophilia* infections in a general hospital: Patient characteristics, antimicrobial susceptibility, and treatment outcome. *PLoS One* 7:e37375. <https://doi.org/10.1371/journal.pone.0037375>
  39. Toleman MA, Bennett PM, Bennett DMC, et al (2007) Global emergence of trimethoprim/sulfamethoxazole resistance in *Stenotrophomonas maltophilia* mediated by acquisition of *sul* genes. *Emerg Infect Dis* 13:559–565. <https://doi.org/10.3201/eid1304.061378>
  40. Nagasundaram N, George Priya Doss C (2013) Predicting the Impact of Single-Nucleotide Polymorphisms in CDK2-Flavopiridol Complex by Molecular Dynamics Analysis. *Cell*

Biochem Biophys 66:681–695. <https://doi.org/10.1007/s12013-012-9512-5>

41. Dasgupta J, Sen U, Dattagupta JK (2003) In silico mutations and molecular dynamics studies on a winged bean chymotrypsin inhibitor protein. *Protein Eng* 16:489–496. <https://doi.org/10.1093/PROTEIN/GZG070>
42. Priya Doss CG, Chakraborty C, Chen L, Zhu H (2014) Integrating in silico prediction methods, molecular docking, and molecular dynamics simulation to predict the impact of ALK missense mutations in structural perspective. *Biomed Res Int* 2014:.. <https://doi.org/10.1155/2014/895831>
43. McCammon JA, Gelin BR, Karplus M (1977) Dynamics of folded proteins. *Nature* 267:585–590. <https://doi.org/10.1038/267585a0>
44. George Priya Doss C, Rajith B, Chakraborty C, et al (2014) In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach. *Mol Biosyst* 10:421–436. <https://doi.org/10.1039/c3mb70427k>
45. Huang M, He JX, Hu HX, et al (2020) Withanolides from the genus *Physalis*: a review on their phytochemical and pharmacological aspects. *J Pharm Pharmacol* 72:649–669. <https://doi.org/10.1111/JPHP.13209>
46. Kuboyama T, Tohda C, Bulletin KKP, 2014 undefined (2014) Effects of Ashwagandha (roots of *Withania somnifera*) on neurodegenerative diseases. *jstage.jst.go.jp* 892:892–897
47. Dhawan M, Parmar M, Sharun K, et al (2021) Medicinal and therapeutic potential of withanolides from *Withania somnifera* against COVID-19. *japsonline.com* 11:6–013. <https://doi.org/10.7324/JAPS.2021.110402>
48. Amezian D (2018) Effect of withanolide-containing diet on gut microbial communities and AMP expression in two closely related Lepidoptera species: *Heliothis subflexa* and
49. Parida PK, Paul D, Chakravorty D (2020) The natural way forward: Molecular dynamics simulation analysis of phytochemicals from Indian medicinal plants as potential inhibitors of SARS-CoV-2 targets. *Phyther Res* 34:3420–3433. <https://doi.org/10.1002/PTR.6868>

**Table 1.** Selected virtual hit compounds based on binding energy, their binding energy and 2D structure

Compounds	Binding Energy (Kcal/mol)	2D structure
27-Deoxywithaferin	-9.98 Kcal/mol	
Withanolide_A	-9.59 Kcal/mol	
Withanolide_Q	-6.14 Kcal/mol	
Withanolide_R	-10.26 Kcal/mol	
Imipenem (Refence compound)	-6.0 Kcal/mol	

**Table 2.** Different interaction bonds formation between ligand and Zn ions.

<b>Compounds</b>	<b>Hydrophobic Interactions</b>	<b>Hydrogen Bonds</b>	<b>Salt Bridges</b>	<b>ZN:A:30 2 (ZN)</b>	<b>ZN:A:30 3 (ZN)</b>
<b>27-Deoxywithaferin</b>	Leu59, Phe145, Ile149, His246, Lys277	-	-	Asp109, His110	His105, His181
<b>Withanolide_A</b>	Tyr32, Trp38, Phe145, His246, Ala249, Tyr270, Ala274	Ile207, Ser208, Lys277	His105, His107, His110, His181, His246	<b>UNL1</b> , Asp109, His110, His246	<b>UNL1</b> , His105, His107, His181
<b>Withanolide_Q</b>	Trp38, Phe145, Pro210, Als249	Ser206, His246	-	Asp109, His110, His246	His105, His107, His181
<b>Withanolide_R</b>	His107, Phe145, Ile149, His246, Ala249, Tyr270, Ala274, Lys277	Leu207, Ser208, His246, Lys277	His105, His107, His110, His181, His246	<b>UNL1</b> , Asp109, His110, His246	<b>UNL1</b> , His105, His107, His181
Imipenem (Refence compound)	Phe145, Pro10	Tyr32, Ser206, Lue207, Ser208	His105, His107, His110, His181, His246	Asp109, His110, His246	His105, His107, His181


**Table 3:** ADMET results for the top 8 compounds after docking studies.

Compound	Dock Score	Lipinski	Ghose	Verber	Egan	Muegge	Pains	Mol. Wt
Demissidine	-9.3	Yes; 1 Violation: MLogP>4.15	No; violation: atoms>70	1 Yes	Yes	No; violation: XLOGP3>5	1 0 alert	399.65 g/mol
Pibenzimol	-9.3	Yes	No; violation: MR>130	1 Yes	Yes	Yes	0 alert	424.50 g/mol
Crinasiatine	-9.2	Yes	Yes	Yes	Yes	Yes	0 alert	359.37 g/mol
Withanolide Q	-9.2	Yes	No; violation: #atoms>70	1 Yes	Yes	Yes	0 alert	470.60 g/mol
Withanolide A	-9.2	Yes	No; violation: #atoms>70	1 Yes	Yes	Yes	0 alert	470.60 g/mol
Withanolide R	-9.1	Yes	No; violation: #atoms>70	1 Yes	Yes	Yes	0 alert	470.60 g/mol
27-Deoxywithaferin	-8.9	Yes	No; violation: #atoms>70	1 Yes	Yes	Yes	0 alert	454.60 g/mol
3-Methylecholanthren	-8.7	Yes; 1 violation: MLogP>4.15	Yes	Yes	Yes	No; violations: XLOGP3>5, Heteroatoms<2	2 0 alert	268.35 g/mol


**Table 4.** MMPBSA binding free energy calculation.

<b>Compounds</b>	<b>Binding energy (kJ/mol)</b>
27-Deoxywithaferin	-28.096 +/- 25.708 kJ/mol
Withanolide_A	-79.777 +/- 7.470 kJ/mol
Withanolide_Q	-29.170 +/- 12.401 kJ/mol
Withanolide_R	-80.003 +/- 10.359 kJ/mol







**Fig. 1** Metallo-beta-lactamase L1 from *Stenotrophomonas maltophilia* protein (PDB ID: 6UAF) downloaded from Protein Data




**Fig. 2** Protein–ligand complex formed by selected hit compounds. All selected hit compounds bond in the same place bear to two Zn atoms (red color)




**Fig. 3** Interaction between protein–ligand (yellow color) and Zn ions (green color). Zn ion 302 showing interaction with protein amino acids. B Zn ion 303 showing interactions with His105 and His181. C. Interaction between 27-deoxywithaferin and side chain of the protein.




**Fig. 4** Interaction between protein–ligand and Zn ions. A Withanolide-A and Zn ion 302 showing interaction with protein amino acids. B Withanolide-A and Zn ion 303




**Fig. 5** Interaction between protein–ligand and Zn ions. A Zn ion 302 showing interaction with protein amino acids. B Zn ion 303 showing interaction with protein



**Fig. 6** Interaction between protein–ligand and Zn ions. A Withanolidine-R and Zn ion 302 showing interaction with protein amino acids. B Withanolidine-R and Zn ion 303




**Fig. 7** The RMSD for the virtual hit four compounds interact with protein and forms a complex




**Fig. 8** The RMSF for the virtual hit compound interacts with protein and forms a complex




## Radius of gyration




**Fig. 9** The radius of gyration for the virtual hit four compounds interact with protein and form a complex



**Fig. 10** Hydrogen bond interaction between protein–ligand complex formed throughout 100 ns MD simulation



**Fig. 11** Hydrogen bond interaction between protein-solvent formed throughout 100 ns MD simulation



**Fig. 12** Secondary structural conformation changes of hit compounds were shown during 100 ns simulation